Literature DB >> 7928456

Muscle-invasive bladder cancer treated with external beam radiotherapy: prognostic factors.

A Pollack1, G K Zagars, D A Swanson.   

Abstract

PURPOSE: To determine the relationship of several potential prognostic factors to the outcome measures of pelvic control, freedom from metastases, and overall survival for bladder cancer patients treated with definitive external beam radiotherapy. METHODS AND MATERIALS: The records of 135 patients treated with high-dose, planned continuous-course, external beam radiotherapy for muscle-invasive transitional cell bladder cancer were reviewed. These patients were treated to an average total dose of 6588 +/- 475 cGy with an average fractional dose of 207 +/- 18 cGy using megavoltage. Median potential follow-up for all patients, including those who died, was 249 months.
RESULTS: The actuarial results at 5 year were 31% pelvic control, 58% freedom from metastases, and 26% overall survival. In the univariate analyses, several factors were correlated with disease outcome including clinical stage, tumor morphology, gross total transurethral resection (TURBT), findings at bimanual exam after TURBT, clinical perivesical extension, age, and clinical complete response at first follow-up cystoscopy (Clinical-CR). A Cox proportional hazards model revealed that only Clinical-CR was independently predictive of pelvic control. In terms of freedom from metastases, only Clinical-CR and clinical stage were significantly associated with outcome in the multivariate analysis. When the multivariate analysis was restricted to T2 and T3 tumors only, then clinical perivesical extension replaced stage as being associated with freedom from metastases. The only factors significantly related to overall survival in the Cox proportional hazards model were Clinical-CR, age, and complete TURBT; stage was of borderline significance when only pretreatment factors were considered.
CONCLUSIONS: Clearly, the most important prognostic factor was Clinical-CR. The pretreatment factors of stage, clinical perivesical extension, and gross total TURBT also correlated with outcome, but, to a lesser degree. For patients medically unfit for radical cystectomy radiotherapy is a viable option, particularly for selected patients. Patients with T4 tumors are poor candidates for definitive radiotherapy and should be treated palliatively if they cannot tolerate systemic therapy.

Entities:  

Mesh:

Year:  1994        PMID: 7928456     DOI: 10.1016/0360-3016(94)90004-3

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

Review 1.  Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.

Authors:  Skyler B Johnson; James B Yu
Journal:  Curr Oncol Rep       Date:  2018-06-30       Impact factor: 5.075

Review 2.  New approaches in the use of radiation therapy in the treatment of infiltrative transitional-cell cancer of the bladder.

Authors:  P Warde; M K Gospodarowicz
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

3.  Effective bladder preservation strategy with low-dose radiation therapy and concurrent intraarterial chemotherapy for muscle-invasive bladder cancer.

Authors:  Hitoshi Ikushima; Seiji Iwamoto; Kyohsuke Osaki; Shunsuke Furutani; Kyoh Yamashita; Takashi Kawanaka; Akiko Kubo; Yoshihiro Takegawa; Takaharu Kudoh; Hiroomi Kanayama; Hiromu Nishitani
Journal:  Radiat Med       Date:  2008-04

Review 4.  Combined chemotherapy and external beam radiotherapy for transitional cell carcinoma of the bladder.

Authors:  Ronald D Ennis
Journal:  Curr Oncol Rep       Date:  2004-05       Impact factor: 5.075

Review 5.  Landmarks in the treatment of muscle-invasive bladder cancer.

Authors:  Niyati Lobo; Chloe Mount; Kawa Omar; Rajesh Nair; Ramesh Thurairaja; Muhammad Shamim Khan
Journal:  Nat Rev Urol       Date:  2017-07-04       Impact factor: 14.432

Review 6.  The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer.

Authors:  Christopher M Russell; Amir H Lebastchi; Tudor Borza; Daniel E Spratt; Todd M Morgan
Journal:  Bladder Cancer       Date:  2016-10-27

Review 7.  Localized and locally advanced bladder cancer.

Authors:  Fabio Calabrò; Cora N Sternberg
Journal:  Curr Treat Options Oncol       Date:  2002-10

Review 8.  Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers.

Authors:  Omar M S El-Taji; Sameer Alam; Syed A Hussain
Journal:  Curr Treat Options Oncol       Date:  2016-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.